ArticlebioRxiv : the preprint server for biology2025
Structural Basis for Childhood Antibody Recognition of The Human Metapneumovirus Fusion Protein.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
Abstract
Human metapneumovirus (hMPV) is a significant cause of acute respiratory illness in children and adults, with the majority of children being seropositive for hMPV by five years of age. Infants, older adults, and immunocompromised individuals are more susceptible to severe hMPV infections that can lead to hospitalization and death. The hMPV fusion (F) protein is the sole target of neutralizing antibodies, and while the most common neutralizing epitopes on the hMPV F protein targeted by B cells in hMPV-infected adults have been previously determined, the antibody response in hMPV-infected children remains undefined. We isolated a panel of human monoclonal antibodies (mAbs) from children previously infected with hMPV (MPV498, MPV499, MPV510, MPV511, and MPV513), and the mAbs were assessed for binding avidity, neutralization potency, epitope specificity, and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.